$0.314
-0.056 (-17.77%)收盤時
- High
- 0.400
- Open
- 0.370
- VWAP
- 0.34
- Vol
- 4.12M
- Mkt Cap
- 56.09M
- Low
- 0.314
- Amount
- 1.41M
- EV/EBITDA, TTM
- 0.00
Enzo Biochem, Inc. is focused on molecular diagnostics and has a portfolio of technical platforms and reagent sets supporting a diverse range of biomedical research and translational science needs. The Company operates through the product segment, which manufactures, develops and markets products and tools for clinical research, translational research, drug development and bioscience research customers worldwide. The Company is engaged in product development and manufactures and supplies a comprehensive portfolio of products, including antibodies, genomic probes, assays, biochemicals and proteins. The Company's products and technologies are used in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry and small molecule chemistry. Its life science division supports the work of research centers and industry partners. It has built a portfolio of intellectual property assets, comprised of around 457 owned patents worldwide.
Analyst Ratings (1)
估值指標
事件時間軸
資訊
8.504-22NewsfilterEnzo Biochem, Inc. Announces Review of Strategic Alternatives after Receiving Multiple Inquiries Regarding a Potential Transaction
9.004-11BenzingaWhy Argenx Shares Are Trading Higher By 5%; Here Are 20 Stocks Moving Premarket
6.504-01NASDAQ.COMThe Zacks Analyst Blog AbbVie, The TJX, The Charles Schwab, Enzo Biochem and CVD Equipment
2.003-31BenzingaWhy Xos Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
- 7.003-28Newsfilter
Enzo Biochem Announces Notification to New York Stock Exchange of Intention to Voluntarily Delist Common Stock and Transfer Trading of Shares to OTCQX
ENZ FAQ — answered by Alphio AI
Enzo Biochem, Inc. is focused on molecular diagnostics and has a portfolio of technical platforms and reagent sets supporting a diverse range of biomedical research and translational science needs. The Company operates through the product segment, which manufactures, develops and markets products and tools for clinical research, translational research, drug development and bioscience research customers worldwide. The Company is engaged in product development and manufactures and supplies a comprehensive portfolio of products, including antibodies, genomic probes, assays, biochemicals and proteins. The Company's products and technologies are used in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry and small molecule chemistry. Its life science division supports the work of research centers and industry partners. It has built a portfolio of intellectual property assets, comprised of around 457 owned patents worldwide. It operates in the Healthcare sector (SERVICES-MEDICAL LABORATORIES industry).
1 analysts cover ENZ: 1 rate it Buy, 0 Hold and 0 Sell.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。